This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human EGF Protein, Mouse IgG2a Fc Tag
catalog :
EGF-H525b
quantity :
1 mg, 100 ug
price :
1910 USD, 290 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
EGF-H525b
product name :
Human EGF Protein, Mouse IgG2a Fc Tag
quantity :
1 mg, 100 ug
price :
1910 USD, 290 USD
quantity & price :
$290/100ug,$1910/1mg (250ug × 4)
target :
EGF
host species :
Human
By Tag :
Mouse IgG Fc Tag
Research :
For Research Use Only
Source :
Human EGF, Mouse IgG2a Fc Tag (EGF-H525b) is expressed from human 293 cells (HEK293). It contains AA Asn 971 - Arg 1023 (Accession # P01133-1).
Endotoxin :
Less than 0.1 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human EGF, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Human epidermal growth factor (EGF) is also known as HOMG4 and URG,and is a growth factor that plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. Epidermal growth factor can be found in human platelets, macrophages, urine, saliva, milk, and plasma. EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. All family members contain one or more repeats of the conserved amino acid sequence. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents. Because of the increased risk of cancer by EGF, inhibiting it decreases cancer risk.
References :
(1) Barnham KJ,et al. 1998, Protein Science 7 (8): 1738–49.
(2) Cotran, Ramzi S.,et al. 2005, Robbins and Cotran pathologic basis of disease.
(3) Dreux AC,et al. 2006, Atherosclerosis 186 (1): 38–53.
(4) Venturi S,et al.2009, Nutrition and Health 20 (2): 119–134.
(5) Herbst RS.et al.2004, International Journal of Radiation Oncology, Biology, Physics 59 (2 Suppl): 21–6.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments